Edition:
Deutschland

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

116.00USD
17 Aug 2018
Change (% chg)

$-1.28 (-1.09%)
Prev Close
$117.28
Open
$117.07
Day's High
$117.28
Day's Low
$115.50
Volume
488,834
Avg. Vol
559,966
52-wk High
$149.17
52-wk Low
$102.21

ALXN.OQ

Chart for ALXN.OQ

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Buy/Sell

Sell Hold Buy
1.83 Mean rating from 18 analysts

Overall

Beta: 1.28
Market Cap(Mil.): $31,536.07
Shares Outstanding(Mil.): 223.19
Dividend: --
Yield (%): --

BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil

* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRIS® (ECULIZUMAB)

Deals of the day-Mergers and acquisitions

April 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

Biotech M&A rolls on as Alexion snaps up Wilson for $855 million

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

UPDATE 2-Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

* U.S. company says first step in rebuilding pipeline (Adds latest shares, analyst reaction)

Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln

April 11 Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.

BRIEF-Alexion To Acquire Wilson Therapeutics

* SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

BRIEF-Alexion Pharmaceuticals Says CEO Ludwig Hantson's Total FY 2017 Compensation Was $15.3 Mln

* ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie +0.71%
Rohstoffe +0.72%
Industrie +0.29%
Konjunktur abhängige Waren & Dienstleistungen +0.63%
Konjunktur unabhängige Waren & Dienstleistungen +0.47%
Finanzindustrie +0.51%
Pharma +0.20%
Technologie +0.30%
Telekommunikation +0.40%